Does Theranos mark the peak of the Silicon Valley bubble?
John Carreyrou talks to Nautilus about the lessons of a $1 billion fraud. BY MICHAEL SEGALMAY 31, 2018 Silicon Valley has a term for startups…
clement31.05.2018
From Rock DJ to Scientist to Entrepreneur: Michael Gilman on The Long Run Podcast
Currently (2018) Michael Gilman is the CEO of two biotech startups – Arrakis Therapeutics, a company attempting to make small molecule drugs against RNA targets;…
clement30.05.2018
Novartis receives U.S. approval for migraine medication
Basel-based pharmaceutical company Novartis has received approval in the USA for its Aimovig migraine medication, developed with its partner, Amgen. It is a new therapeutic…
clement22.05.2018
Basel, a hotspot for biotech and pharma according to Labiotech.eu
Basel is among the European biotech hubs with the most exciting companies as named by labiotech.eu. The industry platform highlighted businesses including Actelion, CRISPR Therapeutics…
clement18.05.2018
Biotech industry continues to grow
The Swiss biotech industry continued to grow in 2017. Reaching record figures in sales and capital investments in companies, according to a new report. New…
clement14.05.2018
Another player emerges in the targeted protein degradation field
Targeted protein degradation is really taking off. Besides Arvinas, C4 Therapeutics, and Kymera, Cedilla Therapeutics, founded by Thirdrock Ventures, has emerged with a $56 million…
clement26.04.2018
IP protection is crucial for business and research
The patent law and attorney-at-law firm Vossius & Partner has been an important partner for BaseLaunch since the inception of the healthcare accelerator in 2016.…
clement24.04.2018
Little by Little: Real Life Lessons In Business Development
This blog was written by Tariq Kassum, COO and Head of Corporate Development at Obsidian Therapeutics, as part of the From The Trenches feature of…
clement17.04.2018
